NCT04236921View on ClinicalTrials.gov

Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

September 11, 2019

Study Completion Date

December 1, 2019

Conditions
Other
Interventions
DRUG

DopaSnap®

immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA

DRUG

RDL of CD-LD

(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),

Trial Locations (1)

H3x 2H9

Syneous Health, Québec

All Listed Sponsors
lead

Riverside Pharmacueticals Corporation

INDUSTRY

NCT04236921 - Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis) | Biotech Hunter | Biotech Hunter